| Followers | 5 |
| Posts | 1540 |
| Boards Moderated | 0 |
| Alias Born | 01/29/2022 |
Friday, May 09, 2025 12:44:46 PM
When the criminals in management live by the criminal sword with O ownership shares of their own company, they must learn the consequences in this criminal world, head in the vice grip, balls to the walls in jail for money laundering short fraud in bed with all the short toxic funders and pretend to be victims of their own crimes this is a promise and dedication for all terminally i’ll cancer patients in need of the only hope for stage 4 metastases cancers and ended up to be a cash cow funneling bonus scam machine profession for all of managements pockets
Recent RNAZ News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/01/2026 12:59:50 PM
- TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer • PR Newswire (US) • 05/27/2026 12:04:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/26/2026 10:46:35 AM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/26/2026 10:43:50 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 08:15:37 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/20/2026 04:15:17 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/08/2026 09:20:58 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 04/30/2026 09:24:06 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 04/30/2026 08:15:15 PM
- TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University • PR Newswire (US) • 04/27/2026 12:02:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/15/2026 08:17:42 PM
- TransCode Therapeutics signs financing deal worth up to $20 million • IH Market News • 04/07/2026 01:51:53 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/07/2026 12:37:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 12:35:16 PM
- TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028 • PR Newswire (US) • 04/07/2026 12:30:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/03/2026 09:06:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 09:05:39 PM
- TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Pa • PR Newswire (US) • 03/03/2026 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2026 01:10:39 PM
- TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development • PR Newswire (US) • 02/23/2026 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2026 01:10:42 PM
- TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138 • PR Newswire (US) • 02/05/2026 01:04:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/06/2026 01:04:38 PM
